Tumor-promoting function of NPAS2 is dependent on HIF-1A activation and the engagement of glycolysis-related genes, indicating that NPAS2 may serve as an important therapeutic target to normalize glucose metabolic aberrations responsible for PCa progression. This evidence concerns the gene NPAS2 and posterior cortical atrophy.